Novartis Will Spin Off Sandoz into Standalone Company

Novartis will separate Sandoz, its generics division, into a standalone company. According to Novartis, the move will improve both companies’ value to shareholders by letting them participate in decision-making for both companies individually. While Sandoz focuses on generics, Novartis will continue to lean into its central therapeutic foci.

According to Emily Kimber, “The standalone Sandoz is expected to be headquartered in Switzerland and listed on the SIX Swiss Exchange, with an American Depositary Receipt (ADR) programme in the US. Richard Saynor would remain chief executive officer following the spin-off.”

To read more, click here.

(Source: PM Live, August 25^th, 2022)